A 5-week treatment, multi-center, double-blind, randomized, placebo-controlled, parallel-group, fixed-dose study of the efficacy, tolerability and safety of dexmethylphenidate HCl extended-release capsules administered once daily in pediatric children with attention-deficit/hyperactivity disorder
Latest Information Update: 19 Nov 2009
At a glance
- Drugs Dexmethylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Novartis
- 13 Nov 2007 Status changed from in progress to completed.
- 14 Nov 2006 Status change
- 19 May 2006 New trial record.